Skip to main content
Top
Published in: Diabetologia 11/2007

01-11-2007 | Article

Association of fasting glucagon and proinsulin concentrations with insulin resistance

Authors: E. Ferrannini, E. Muscelli, A. Natali, R. Gabriel, A. Mitrakou, A. Flyvbjerg, A. Golay, K. Hojlund, The Relationship between Insulin Sensitivity and Cardiovascular Disease Risk (RISC) Project Investigators

Published in: Diabetologia | Issue 11/2007

Login to get access

Abstract

Aims/hypothesis

Hyperproinsulinaemia and relative hyperglucagonaemia are features of type 2 diabetes. We hypothesised that raised fasting glucagon and proinsulin concentrations may be associated with insulin resistance (IR) in non-diabetic individuals.

Methods

We measured IR [by a euglycaemic–hyperinsulinaemic (240 pmol min−1 m−2) clamp technique] in 1,296 non-diabetic (on a 75 g OGTT) individuals [716 women and 579 men, mean age 44 years, BMI 26 kg/m2 (range 18–44 kg/m2)] recruited at 19 centres in 14 European countries. IR was related to fasting proinsulin or pancreatic glucagon concentrations in univariate and multivariate analyses. Given its known relationship to IR, serum adiponectin was used as a positive control.

Results

In either sex, both glucagon and proinsulin were directly related to IR, while adiponectin was negatively associated with it (all p < 0.0001). In multivariate models, controlling for known determinants of insulin sensitivity (i.e. sex, age, BMI and glucose tolerance) as well as factors potentially affecting glucagon and proinsulin (i.e. fasting plasma glucose and C-peptide concentrations), glucagon and proinsulin were still positively associated, and adiponectin was negatively associated, with IR. Finally, when these associations were tested as the probability that individuals in the top IR quartile would have hormone levels in the top quartile of their distribution independently of covariates, the odds ratio was ∼2 for both glucagon (p = 0.05) and proinsulin (p = 0.02) and 0.36 for adiponectin (p < 0.0001).

Conclusions/interpretation

Whole-body IR is independently associated with raised fasting plasma glucagon and proinsulin concentrations, possibly as a result of IR at the level of alpha cells and beta cells in pancreatic islets.
Appendix
Available only for authorised users
Literature
1.
go back to reference Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB (1987) Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64:106–110CrossRefPubMed Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB (1987) Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64:106–110CrossRefPubMed
2.
go back to reference Aronoff SL, Bennett PH, Unger RH (1977) Immunoreactive glucagon (IRG) responses to intravenous glucose in prediabetes and diabetes among Pima Indians and normal Caucasians. J Clin Endocrinol Metab 44:968–972CrossRefPubMed Aronoff SL, Bennett PH, Unger RH (1977) Immunoreactive glucagon (IRG) responses to intravenous glucose in prediabetes and diabetes among Pima Indians and normal Caucasians. J Clin Endocrinol Metab 44:968–972CrossRefPubMed
3.
go back to reference Mitrakou A, Kelley D, Mokan M et al (1992) Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326:22–29CrossRefPubMed Mitrakou A, Kelley D, Mokan M et al (1992) Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326:22–29CrossRefPubMed
4.
go back to reference Cherrington AD (1997) Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 48:1198–1214CrossRef Cherrington AD (1997) Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 48:1198–1214CrossRef
5.
go back to reference Ahrén B, Larsson H (2000) Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance. Diabetes Care 23:650–657CrossRefPubMed Ahrén B, Larsson H (2000) Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance. Diabetes Care 23:650–657CrossRefPubMed
6.
go back to reference Ahrén B (2006) Glucagon secretion in relation to insulin sensitivity in healthy subjects. Diabetologia 49:117–122CrossRefPubMed Ahrén B (2006) Glucagon secretion in relation to insulin sensitivity in healthy subjects. Diabetologia 49:117–122CrossRefPubMed
7.
go back to reference Mako ME, Starr JI, Rubenstein AH (1977) Circulating proinsulin in patients with maturity onset diabetes. Am J Med 63:865–869CrossRefPubMed Mako ME, Starr JI, Rubenstein AH (1977) Circulating proinsulin in patients with maturity onset diabetes. Am J Med 63:865–869CrossRefPubMed
8.
go back to reference Yoshioka N, Kuzuya T, Matsuda A, Taniguchi M, Iwamoto Y (1988) Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 31:355–360CrossRefPubMed Yoshioka N, Kuzuya T, Matsuda A, Taniguchi M, Iwamoto Y (1988) Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 31:355–360CrossRefPubMed
9.
go back to reference Porte D Jr, Kahn SE (1989) Hyperproinsulinemia and amyloid in NIDDM. Clues to etiology of islet beta cell dysfunction? Diabetes 38:1333–1336CrossRefPubMed Porte D Jr, Kahn SE (1989) Hyperproinsulinemia and amyloid in NIDDM. Clues to etiology of islet beta cell dysfunction? Diabetes 38:1333–1336CrossRefPubMed
10.
go back to reference Pradhan AD, Manson JE, Meigs JB et al (2003) Insulin, proinsulin, proinsulin:insulin ratio, and the risk of developing type 2 diabetes mellitus in women. Am J Med 114:438–444CrossRefPubMed Pradhan AD, Manson JE, Meigs JB et al (2003) Insulin, proinsulin, proinsulin:insulin ratio, and the risk of developing type 2 diabetes mellitus in women. Am J Med 114:438–444CrossRefPubMed
11.
go back to reference Hanley AJ, D'Agostino R Jr, Wagenknecht LE, Saad MF, Savage PJ, Bergman R, Haffner SM; Insulin Resistance Atherosclerosis Study (2002) Increased proinsulin levels and decreased acute insulin response independently predict the incidence of type 2 diabetes in the insulin resistance atherosclerosis study. Diabetes 51:1263–1270CrossRefPubMed Hanley AJ, D'Agostino R Jr, Wagenknecht LE, Saad MF, Savage PJ, Bergman R, Haffner SM; Insulin Resistance Atherosclerosis Study (2002) Increased proinsulin levels and decreased acute insulin response independently predict the incidence of type 2 diabetes in the insulin resistance atherosclerosis study. Diabetes 51:1263–1270CrossRefPubMed
12.
go back to reference Rhodes CJ, Alarcon C (1994) What beta cell defect could lead to hyperproinsulinemia in NIDDM? Some clues from recent advances made in understanding the proinsulin processing mechanism. Diabetes 43:511–517CrossRefPubMed Rhodes CJ, Alarcon C (1994) What beta cell defect could lead to hyperproinsulinemia in NIDDM? Some clues from recent advances made in understanding the proinsulin processing mechanism. Diabetes 43:511–517CrossRefPubMed
13.
go back to reference Alarcon C, Leahy JL, Schuppin GT, Rhodes CJ (1995) Increased secretory demand rather than a defect in the proinsulin conversion mechanism causes hyperproinsulinemia in a glucose-infusion rat model of non-insulin-dependent diabetes mellitus. J Clin Invest 95:1032–1039CrossRefPubMedPubMedCentral Alarcon C, Leahy JL, Schuppin GT, Rhodes CJ (1995) Increased secretory demand rather than a defect in the proinsulin conversion mechanism causes hyperproinsulinemia in a glucose-infusion rat model of non-insulin-dependent diabetes mellitus. J Clin Invest 95:1032–1039CrossRefPubMedPubMedCentral
14.
go back to reference Hills SA, Balkau B, Coppack SW et al (2004) The EGIR-RISC study (The European Group for the Study of Insulin Resistance: Relationship between Insulin Sensitivity and Cardiovascular Disease Risk): I. Methodology and objectives. Diabetologia 47:566–570CrossRefPubMed Hills SA, Balkau B, Coppack SW et al (2004) The EGIR-RISC study (The European Group for the Study of Insulin Resistance: Relationship between Insulin Sensitivity and Cardiovascular Disease Risk): I. Methodology and objectives. Diabetologia 47:566–570CrossRefPubMed
15.
go back to reference Frystyk J, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A (2005) Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 48:1911–1918CrossRefPubMed Frystyk J, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A (2005) Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 48:1911–1918CrossRefPubMed
16.
go back to reference Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2000) Diabetes Care 23(Suppl 1):S4–S19 Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2000) Diabetes Care 23(Suppl 1):S4–S19
17.
18.
go back to reference Olsen HL, Theander S, Bokvist K, Buschard K, Wollheim CB, Gromada J (2005) Glucose stimulates glucagon release in single rat alpha-cells by mechanisms that mirror the stimulus-secretion coupling in beta-cells. Endocrinology 146:4861–4870CrossRefPubMed Olsen HL, Theander S, Bokvist K, Buschard K, Wollheim CB, Gromada J (2005) Glucose stimulates glucagon release in single rat alpha-cells by mechanisms that mirror the stimulus-secretion coupling in beta-cells. Endocrinology 146:4861–4870CrossRefPubMed
19.
go back to reference Gromada J, Franklin I, Wollheim CB (2007) Alpha cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 28:84–116CrossRefPubMed Gromada J, Franklin I, Wollheim CB (2007) Alpha cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 28:84–116CrossRefPubMed
20.
go back to reference Groop LC, Ferrannini E (1993) Insulin action and substrate competition. Baillieres Clin Endocrinol Metab 7:1007–1032CrossRefPubMed Groop LC, Ferrannini E (1993) Insulin action and substrate competition. Baillieres Clin Endocrinol Metab 7:1007–1032CrossRefPubMed
21.
go back to reference Ferrannini E, DeFronzo RA, Sherwin RS (1982) Transient hepatic response to glucagon in man: role of insulin and hyperglycemia. Am J Physiol 242:E73–E81PubMed Ferrannini E, DeFronzo RA, Sherwin RS (1982) Transient hepatic response to glucagon in man: role of insulin and hyperglycemia. Am J Physiol 242:E73–E81PubMed
22.
go back to reference Chen SS, Zhang Y, Santomango TS, Williams PE, Lacy DB, McGuinness OP (2007) Glucagon chronically impairs hepatic and muscle glucose uptake. Am J Physiol Endocrinol Metab 292:E928–E935CrossRefPubMed Chen SS, Zhang Y, Santomango TS, Williams PE, Lacy DB, McGuinness OP (2007) Glucagon chronically impairs hepatic and muscle glucose uptake. Am J Physiol Endocrinol Metab 292:E928–E935CrossRefPubMed
23.
go back to reference Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR (1999) Tissue-specific knockout of the insulin receptor in pancreatic β cells creates an insulin secretory defect similar to that of type 2 diabetes. Cell 96:329–339CrossRefPubMed Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR (1999) Tissue-specific knockout of the insulin receptor in pancreatic β cells creates an insulin secretory defect similar to that of type 2 diabetes. Cell 96:329–339CrossRefPubMed
24.
go back to reference Ueki K, Okada T, Hu J, Liew CW et al (2006) Total insulin and IGF-1 resistance in pancreatic β cells caused overt diabetes. Nat Gen 38:583–588CrossRef Ueki K, Okada T, Hu J, Liew CW et al (2006) Total insulin and IGF-1 resistance in pancreatic β cells caused overt diabetes. Nat Gen 38:583–588CrossRef
25.
go back to reference Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G (1997) Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 100:1166–1173CrossRefPubMedPubMedCentral Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G (1997) Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 100:1166–1173CrossRefPubMedPubMedCentral
26.
go back to reference Ferrannini E, Camastra S, Gastaldelli A et al (2004) Beta-cell function in obesity: effects of weight loss. Diabetes 53(Suppl 3):S26–S33CrossRefPubMed Ferrannini E, Camastra S, Gastaldelli A et al (2004) Beta-cell function in obesity: effects of weight loss. Diabetes 53(Suppl 3):S26–S33CrossRefPubMed
27.
go back to reference Rana JS, Li TY, Manson JE, Hu FB (2007) Adiposity compared with physical inactivity and risk of type 2 diabetes in women. Diabetes Care 30:53–58CrossRefPubMed Rana JS, Li TY, Manson JE, Hu FB (2007) Adiposity compared with physical inactivity and risk of type 2 diabetes in women. Diabetes Care 30:53–58CrossRefPubMed
Metadata
Title
Association of fasting glucagon and proinsulin concentrations with insulin resistance
Authors
E. Ferrannini
E. Muscelli
A. Natali
R. Gabriel
A. Mitrakou
A. Flyvbjerg
A. Golay
K. Hojlund
The Relationship between Insulin Sensitivity and Cardiovascular Disease Risk (RISC) Project Investigators
Publication date
01-11-2007
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 11/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0806-x

Other articles of this Issue 11/2007

Diabetologia 11/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.